SecBot SecBot
6-K ·Filed Apr 20, 2026

AAVXF

Abivax S.A.
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001956827-26-000014
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine regulatory filing. Traders should monitor the company's website for the release of the full preparatory documents ahead of the May 11 shareholder meeting, where potential dividend, governance, or equity-related proposals may be revealed.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
AAVXF ▲ +20.19% at T+60d
NEUTRAL call +20.19% · α vs SPY +13.29% · entry $115.65 → $139.00
Entry = T+0 close
Apr 20, 2026
via day close
T+1d
0.00%
call 0.00% · α -1.02%
$115.65
settled 6mo ago
T+5d
0.00%
call 0.00% · α -1.08%
$115.65
settled 6mo ago
T+20d
0.00%
call 0.00% · α -4.92%
$115.65
settled 5mo ago
T+60d
+20.19%
call +20.19% · α +13.29%
$139.00
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Abivax S.A. filed a 6-K to announce the availability of preparatory documents for its Annual Ordinary and Extraordinary General Meeting scheduled for May 11, 2026. The filing is a routine procedural notice and does not contain material financial or operational updates.

Key Facts

  • Abivax filed a 6-K on April 20, 2026, to announce the availability of preparatory documents for its upcoming Annual General Meeting on May 11, 2026.
  • The meeting will be held in Paris, France, and includes both ordinary and extraordinary agenda items.
  • No financial results, strategic changes, or material corporate actions were disclosed in the filing.
  • The preparatory documents are available on the company's website as required by French regulatory rules.

Financial Impact

No immediate financial impact; no new financial data or capital allocation decisions disclosed.

Risk Factors

  • Information in the preparatory documents, once released, could include unexpected proposals such as dilutive financings or governance changes.
  • Failure to file complete documents on time could lead to regulatory scrutiny or shareholder concerns.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001956827-26-000014
Document: a260420_abivaxxprxagmprepa.htm0001956827-26-000014
Document: 0001956827-26-000014-index-headers.html0001956827-26-000014
Document: 0001956827-26-000014-index.html0001956827-26-000014
Document: 0001956827-26-000014.txt0001956827-26-000014
3 reports for AAVXF
Performance horizon
Filters
Rows
Reports for AAVXF — sortable, filterable
TypeNow
May 22, 2026
22w ago
6-K
NEUTRAL ★ 5/10
$126.00 $101.25▼ −19.64%▼ −17.69%$139.00 (+10.32%)
May 20, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$126.00 $101.25▼ −19.64%▼ −19.98%$139.00 (+10.32%)
Apr 20, 2026
27w ago
6-K
NEUTRAL ★ 2/10
$115.65 $115.65· 0.00%▼ −4.92%$139.00 (+20.19%)
Showing 3 of 3

US Market Status

Market Closed — Opens Wed (12h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026